8-K: STAAR Surgical Terminates Alcon Merger After Shareholder Vote

STAAR Surgical announced its intent to terminate the merger agreement with Alcon after failing to secure the necessary stockholder votes at a special meeting.

Summary

• STAAR Surgical Company held a special meeting of stockholders on January 6, 2026, to consider proposals related to its merger agreement with Alcon Research, LLC.
• Based on preliminary estimates, STAAR did not receive the necessary stockholder votes to approve the merger agreement.
• STAAR Surgical intends to terminate the merger agreement with Alcon.
• No termination fee will be payable by either party as a result of this termination.
• STAAR Surgical will remain a standalone, publicly traded company and continue to trade on Nasdaq under the ticker symbol STAA.

Sentiment

Score: 4

Explanation: The failure of the merger agreement, which the Board had deemed in the best interest of stockholders, is a negative event. However, the absence of a termination fee and management's stated commitment to maximizing standalone value and leveraging its 'best in class' technology mitigate the negative impact. The company will continue its operations independently.

Positives

• No termination fee is payable by either party, avoiding financial penalties for STAAR Surgical.
• STAAR Surgical retains its independence and its proprietary EVO ICL technology, continuing as a standalone company.
• Management expressed commitment to maximizing stockholder value and realizing the full potential of STAAR's innovative technology.
• The company plans to prioritize profitable sales growth and drive efficiencies through its distribution network.
• Management believes its EVO ICL technology is 'best in class' and aims for its more extensive worldwide use.

Negatives

• The proposed merger with Alcon, which the Board had determined was in the best interests of STAAR stockholders, will not proceed.
• STAAR Surgical will not benefit from the potential synergies, scale, or market reach that the merger with Alcon might have offered.

Future Outlook

STAAR Surgical's management is committed to maximizing stockholder value and realizing the full potential of its innovative EVO ICL technology as a standalone company. The company plans to prioritize profitable sales growth and drive efficiencies through its distribution network, aiming for more extensive worldwide use of its EVO ICL technology.

Management Comments

• "The Board approved the Alcon agreement because we determined that it was in the best interests of STAAR stockholders. We respect the outcome of the vote and look forward to working collaboratively with shareholders to ensure the best possible outcome for STAAR as a stand-alone company." Stephen Farrell, CEO.
• "We remain committed to maximizing stockholder value and realizing the full potential of STAARs innovative technology." Stephen Farrell, CEO.
• "STAAR has a dedicated and loyal team that will compete successfully, and our EVO ICL technology is best in class." Stephen Farrell, CEO.
• "In the short term, we will continue to prioritize profitable sales growth while we drive efficiencies through our distribution network. Our EVO ICL technology should be used more extensively worldwide, and it is our mission to achieve that objective." Stephen Farrell, CEO.

Industry Context

STAAR Surgical operates in the ophthalmic surgery and vision correction industry, specializing in phakic IOLs with its EVO ICL technology. The termination of the merger with Alcon, a major player in eye care, means STAAR will continue to compete independently in a market driven by technological innovation and global expansion opportunities for advanced vision correction solutions.

Stakeholder Impact

• Shareholders: The merger, which the Board believed was in their best interest, will not proceed. They retain ownership in a standalone STAAR Surgical. Management has committed to maximizing shareholder value as an independent entity.
• Employees: The company will continue as a standalone entity, with management noting a 'dedicated and loyal team that will compete successfully.'
• Customers: STAAR will continue to provide its EVO ICL technology, with a stated mission to achieve more extensive worldwide use.

Next Steps

• STAAR Surgical intends to formally terminate the merger agreement with Alcon.
• The company will file final certified voting results from the Special Meeting in a future Form 8-K.
• Management plans to work collaboratively with shareholders to ensure the best possible outcome for STAAR as a stand-alone company.
• The company will prioritize profitable sales growth and drive efficiencies through its distribution network.
• STAAR aims to achieve more extensive worldwide use of its EVO ICL technology.

Key Dates

Recommendation

The termination of the Alcon merger, while potentially disappointing given the Board's prior endorsement, removes uncertainty regarding the transaction. STAAR Surgical will continue as an independent entity with a stated commitment to profitable growth and leveraging its 'best in class' EVO ICL technology. The absence of a termination fee is a positive. Investors should hold to observe the company's execution on its standalone strategy and assess its ability to deliver on its growth objectives without the Alcon partnership.

Keywords

STAAR Surgical, Alcon, Merger Termination, Stockholder Vote, EVO ICL, Phakic IOLs, Vision Correction, Ophthalmic Surgery, Medical Devices